oa SA Pharmaceutical Journal - New drug focus

Volume 73, Issue 8
  • ISSN : 2221-5875
  • E-ISSN: 2220-1017



Extracted from text ... SA Pharmaceutical Journal - September 2006 58 DRUG INFO Information supplied by Amayeza Info Services Tel : (011) 678 2332 Prexige(r) - A new COX-2 inhibitor Approved indication Prexige(r) contains lumiracoxib. It is the first COX-2 inhibitor to obtain regulatory approval since the global withdrawal of rofecoxib. Lumiracoxib is indicated for the symptomatic treatment of osteoarthritis, the treatment of post-operative pain following dental or orthopaedic surgery and for the treatment of primary dysmenorrhoea. Mode of action Lumiracoxib is a nonsteroidal anti-inflammatory agent (NSAID). Clinical benefits e.g. analgesic and anti-inflammatory effects of NSAIDs, are related to inhibition of cyclooxygenase 2 ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error